Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis.
Biomark Med
; 17(10): 497-507, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-37526144
ABSTRACT
Background:
The impact of lymphocyte-C-reactive protein ratio (LCR) on clinical outcomes has been reported in liver cancer such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), but the results remain inconsistent.Methods:
We searched PubMed, Scopus, Web of Science, Embase and Cochrane Library databases for relevant studies evaluating the association of LCR with survival outcomes and clinicopathological parameters.Results:
Eight studies with 4316 patients were included in this meta-analysis. Low LCR was significantly associated with poor overall survival, disease-free survival/relapse-free survival and disease progression clinicopathological parameters in patients with HCC or ICC.Conclusion:
Low pretreatment LCR was an adverse prognostic indicator in patients with HCC or ICC. In addition, it was correlated with clinicopathological parameters indicating a higher stage of malignancy.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bile Duct Neoplasms
/
Cholangiocarcinoma
/
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Biomark Med
Journal subject:
BIOQUIMICA
/
MEDICINA
Year:
2023
Document type:
Article
Affiliation country:
China